Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.64 |
| ▸ | PPARG | P37231 | 11/20 | 0.64 |
| ▸ | PPARA | Q07869 | 10/20 | 0.64 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219965 | 1.00 | PPARD (0.64) | PPARDPPARGPPARAPCSK9PHGDH | |
| SCHEMBL10219966 | 1.00 | PPARD (0.64) | PPARDPPARGPPARAPCSK9PHGDH | |
| SCHEMBL10219971 | 0.93 | PPARD (0.65) | PPARDPPARGPPARAPCSK9PHGDH | |
| SCHEMBL10219967 | 0.93 | PPARD (0.65) | PPARDPPARGPPARAPCSK9PHGDH | |
| SCHEMBL10219972 | 0.93 | PPARD (0.62) | PPARDPPARGPPARAPCSK9PHGDH | |
| SCHEMBL10219980 | 0.91 | PPARD (0.62) | PPARDPPARGPPARAPCSK9PHGDH | |
| SCHEMBL10219943 | 0.90 | PPARD (0.79) | PPARDPPARGPPARAPHGDH | |
| SCHEMBL10219469 | 0.86 | PPARD (0.63) | PPARDPPARGPPARAPCSK9MAPT | |
| SCHEMBL10219465 | 0.86 | PPARD (0.63) | PPARDPPARGPPARAPCSK9MAPT | |
| SCHEMBL10219477 | 0.86 | PPARD (0.63) | PPARDPPARGPPARAPCSK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.